Scientech Research LLC’s enGene Therapeutics ENGN Stock Holding History

Scientech Research LLC’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$70.4K	Buy	+40,710	New	+$166K	0.06%	185

Other funds holding ENGN

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Scientech Research LLC's ENGN Position: Q2 2026 in Review

Scientech Research LLC opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 40,710 shares worth $70.4K. The stake represents 0.06% of the portfolio and ranks #185 among its holdings.

60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

Scientech Research LLC held 40,710 shares of enGene Therapeutics worth $70.4K as of Q2 2026.
enGene Therapeutics was a new Scientech Research LLC position in Q2 2026.
enGene Therapeutics made up 0.06% of Scientech Research LLC's portfolio in Q2 2026, its #185 holding.
60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Scientech Research LLC's 13F filing for Q2 2026, filed 14 Aug 2026.